Table 2.

Univariate analyses of prognostic factors for DFS and OS

Variable	DFS			OS
	HR	95% CI	P-value	HR	95% CI	P-value
Gender
Female	1			1
Male	1.03	0.80–1.33	0.81	1.22	0.94–1.59	0.13
Age
≤50 years	1			1
>50 years	0.94	0.73–1.21	0.63	1.01	0.77–1.32	0.94
Site of primary lesion
Extremity	1			1
Head/neck	0.77	0.53–1.11	0.16	0.81	0.55–1.18	0.26
Trunk	1.34	0.99–1.82	0.06	1.30	0.95–1.78	0.11
Other	0.54	0.22–2.20	0.54	0.49	0.11–1.97	0.31
Unknown	0.73	0.63–1.38	0.73	0.70	0.45–1.08	0.10
MUP
No	1			1
Yes	0.92	0.64–1.31	0.63	0.68	0.45–1.03	0.07
Breslow
T1	1			1
T2	1.37	0.85–2.21	0.20	1.54	0.91–2.63	0.11
T3	1.78	1.10–2.89	0.02	1.80	1.05–3.07	0.03
T4	1.18	0.72–1.94	0.51	1.62	0.95–2.76	0.08
MUP	1.21	0.72–2.06	0.47	1.08	0.59–1.97	0.81
Histology
SSM	1			1
NM	1.07	0.74–1.55	0.73	1.10	0.75–1.61	0.64
MUP	0.91	0.59–1.41	0.68	0.71	0.44–1.15	0.16
Other	0.70	0.36–1.39	0.31	0.94	0.49–1.82	0.85
Clark level
II	1			1
III	0.88	0.46–1.69	0.70	1.16	0.55–2.45	0.70
IV	0.96	0.51–1.80	0.90	1.11	0.54–2.29	0.78
V	0.85	0.41–1.73	0.64	1.12	0.51–2.51	0.77
MUP	0.83	0.42–1.64	0.60	0.79	0.36–1.74	0.55
Ulceration
Absent	1			1
Present	1.21	0.90–1.63	0.2	1.48	1.10–1.99	0.01
Site of TLND
Inguinal	1			1
Iliac	0.97	0.47–1.98	0.93	0.96	0.49–1.87	0.90
Ilioinguinal	0.76	0.50–1.14	0.18	0.71	0.47–1.07	0.10
Axillary	1.14	0.73–1.76	0.57	1.06	0.68–1.67	0.78
Neck	0.63	0.41–0.97	0.04	0.61	0.39–0.94	0.03
No. of collected nodes	1.00	0.99–1.01	0.54	1.00	0.99–1.01	0.65
AJCC staging
N1	1			1
N2	1.34	0.98–2.50	0.07	1.33	0.96–1.84	0.09
N3	1.90	1.39–2.58	<0.001	1.97	1.43–2.72	<0.001
LN ratio	2.35	1.51–3.64	<0.001	2.83	1.80–4.45	<0.001
ECE
Absent	1			1
Present	1.60	1.23–2.08	<0.001	1.83	1.39–2.40	<0.001
Adjuvant radiotherapy
No	1			1
Yes	1.13	0.83–1.53	0.45	1.18	0.85–1.63	0.33

HR hazard ratio, CI confidence interval, SSM superficial spreading melanoma, NM nodular melanoma, LN lymph node